Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03450187 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study

A Phase 1 study of Bacterial Infections, sponsored by Tetraphase Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT03450187 is a Phase 1 study of Bacterial Infections that has completed, run by Tetraphase Pharmaceuticals. The registered enrollment target is 40 participants, below the 139-participant average among 17 other Bacterial Infections trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03450187, a Phase 1 study of Bacterial Infections, has completed, sponsored by Tetraphase Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This is a phase 1, single-center, randomized, placebo-controlled, double-blind, multiple ascending-dose study to assess the safety, tolerability, and PK of oral TP-271 in healthy adult subjects. Male or female subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be enrolled in this study.

Conditions Studied

Interventions

  • DRUG TP-271

Study Locations (1)

Texas

  • PPD Phase I Clinic - Austin

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2018-03-20
Est. Completion 2019-03-31
Phase Phase 1

Sponsor

Tetraphase Pharmaceuticals

13 total trials

What the Registry Record Tells You About NCT03450187

The ClinicalTrials.gov registry entry for NCT03450187 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 17 other Bacterial Infections trials with a reported enrollment target (71% lower). The listed sponsor is Tetraphase Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bacterial Infections appearing as the primary indexed condition, and to 1 intervention - of which TP-271 is the first listed.

NCT03450187 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03450187 about?

NCT03450187 is a clinical study titled "A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study". This is a phase 1, single-center, randomized, placebo-controlled, double-blind, multiple ascending-dose study to assess the safety, tolerability, and PK of oral TP-271 in healthy adult subjects. Male or female subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be enrolled...

What is the current status of trial NCT03450187?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-03-20. Estimated completion is 2019-03-31.

What conditions does trial NCT03450187 study?

This clinical trial studies the following conditions: Bacterial Infections.

What interventions are being tested in trial NCT03450187?

The interventions under investigation include: TP-271 (DRUG).

Who is sponsoring clinical trial NCT03450187?

This trial is sponsored by Tetraphase Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03450187 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bacterial Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.